T he global prevalence of atrial fibrillation (AF) and its associated costs are growing. [1] [2] [3] [4] [5] [6] [7] The identification of novel, modifiable risk factors may reveal new therapeutic targets for arrhythmia prevention. Alterations in mineral metabolism are particularly promising.
CKD with incident AF can be explained, in part, by elevated concentrations of FGF-23.
Methods

Study Population
MESA and CHS are community-based cohort studies designed to assess risk factors for cardiovascular disease. 20, 21 Between 2000 and 2002, MESA enrolled 6814 participants 45 to 84 years of age who were free of baseline cardiovascular disease, defined as physician-diagnosed myocardial infarction, angina or nitroglycerin use, stroke or transient ischemic attack, heart failure, current AF, or having undergone cardiovascular procedures (coronary artery bypass grafting, angioplasty, valve replacement, pacemaker or defibrillator implantation, any surgery on the heart or arteries). Participants were recruited by race/ethnicity (white, black, Hispanic, and Chinese descents) and were drawn from 6 US regions. FGF-23 concentrations were measured for 6552 MESA participants with frozen serum available at baseline. From this group, we excluded 2 participants with estimated glomerular filtration rate (eGFR) <15 mL·min −1 ·1.73 m −2 and 3 participants with implausibly high FGF-23 concentrations. We eliminated another 149 additional participants with ≥1 of the following: a self-reported history of transient AF before enrollment (n=55), AF noted at the baseline examination (n=1), or no follow-up for incident AF (n=98). After these exclusions, there were 6398 participants left in our analysis cohort.
CHS enrolled 5201 patients ≥65 years of age between 1989 and 1990 from 4 US communities. An additional 687 black participants were enrolled between 1992 and 1993. FGF-23 was measured for 3337 participants with frozen plasma available from the 1996-1997 follow-up study visit (baseline for the present study). From this group, we excluded 1987 participants with prevalent cardiovascular disease at the 1996-1997 visit, defined as coronary artery disease, heart failure, stroke/transient ischemic attack, claudication, AF, and pacemaker implantation, leaving 1350 participants in our analysis cohort.
The institutional review board at each site approved the respective study, and all participants provided written informed consent.
Fibroblast Growth Factor-23
For MESA, FGF-23 was measured in previously unthawed serum using the Kainos immunoassay, which detects the full-length, biologically intact FGF-23 molecule via midmolecule and distal epitopes. Assays were performed in 2011 with interassay coefficients of variation for singlicate high and low control samples of 6.7% and 12.4%, respectively. 22 For CHS, FGF-23 was measured in previously unthawed plasma using the Immutopics C-terminal ELISA kit (Immutopics, San Clemente, CA).
14 Assays were performed in 2010, with intra-assay and interassay coefficients of variation of 7.4% and 10.6%, respectively. 14 
Atrial Fibrillation
Incident AF was identified by systematic reviews of hospital discharge diagnoses, inpatient and outpatient physician claims data, and study ECGs. In MESA, these measures included review of hospitalization discharge diagnoses obtained during event data collection supplemented by study ECGs as well as incident event dates identified from inpatient and outpatient physician claims data. In CHS, these measures included annual study ECGs from 1996 to 1999, hospital discharge diagnoses during CHS event data collection, and inpatient, outpatient, and physician claims diagnoses of AF for participants enrolled in feefor-service Medicare. ECGs in both studies were read at a centralized ECG reading center, EPICARE, at Wake Forest University. AF or atrial flutter that occurred during hospitalization for coronary bypass graft surgery or valve replacement surgery was excluded.
Covariates
All covariates were ascertained at the time of FGF-23 measurement unless otherwise specified. Age, sex, race/ethnicity, highest attained education, smoking status, physical activity, and medication use were self-reported by questionnaire. Diabetes mellitus was defined as fasting glucose ≥126 mg/dL or the use of hypoglycemic medications. eGFR was calculated using serum concentrations of both creatinine and cystatin C equations to maximize precision. 23 Urine albumin excretion was quantified as the ratio of albumin to creatinine (ACR) in a single-voided urine sample. Serum calcium and phosphate were measured by indirect potentiometry on a DxC Synchron analyzer (Beckman-Coulter Inc, Brea, CA) and timed-rate colorimetric reaction method, respectively. 24 Serum 25-hydroxyvitamin D was measured by mass spectrometry. 25 Serum parathyroid hormone (PTH) was measured by Beckman-Coulter DxI automated 2-site immunoassay (Beckman-Coulter, Inc). 26 In CHS, left atrial diameter was measured in 1256 participants (93%), and left ventricular end-diastolic (LVED) mass and diameter were derived in 950 participants (70%) in 1994-1995 (2 years prior to FGF-23 measurements) using M-mode and 2-dimensional echocardiography. 20 Left ventricular mass was determined using an autopsyvalidated formula. 27 All study echocardiograms were interpreted at the CHS Echocardiography Reading Center at the University of Maryland. 20 In MESA, LVED mass and volume were measured in 5003 participants by cardiac magnetic resonance imaging using 1.5-T magnets by blinded, central readers applying commercial software (MASS 4.2, Leiden, the Netherlands). 28 In both cohorts, a congestive heart failure event was defined as a physician diagnosis of heart failure, medical treatment for heart failure, and clinical signs or symptoms of heart failure.
14,28
Statistical Methods
MESA participants were considered at risk of incident AF from their baseline visit (2000-2002) until April 13, 2011. CHS participants were considered at risk from the 1996-1997 study visit (baseline for this study) until December 31, 2006 . Unadjusted incidence rates of AF were calculated for each cohort and for each FGF-23 quartile.
Cox proportional hazard models were applied to test associations of FGF-23 with the hazard of developing AF during follow-up. Serial multivariable models were constructed. Initially, we adjusted for demographic data, including age (continuous), sex, race/ethnicity, study site, and education (high school or less, high school to some college, college degree or more [29] [30] [31] To explore factors that may mediate the association of FGF-23 with AF, we performed additional analyses adjusted for LVED mass, volume, or diameter, as well as interim congestive heart failure events, N-terminal pro-B-type natriuretic peptide, C-reactive protein, left atrial diameter (CHS only), or interleukin-6 (MESA only).
Functional forms of the relationships between FGF-23 and incident AF were explored with the use of penalized spline plots. We tested for heterogeneity by age, sex, race/ethnicity, eGFR, urine ACR, and CKD (eGFR <60 mL·min −1 ·1.73 m −2 , urine ACR ≥30 mg/g, or both) 14 by including interaction terms of FGF-23 with each covariate, testing statistical significance with the Wald test. Additionally, to explore whether FGF-23 may mediate known associations of low eGFR with AF, 19 we assessed the association of eGFR <60 mL·min −1 ·1.73 m −2 with the hazard of AF without and with adjustment for FGF-23.
Approximately 5% of subjects were missing covariate data on education, smoking, urine albumin, low-density lipoprotein cholesterol, by guest on January 13, 2018 http://circ.ahajournals.org/ Downloaded from July 22, 2014 or serum creatinine. In CHS, 58.4%, 58.3%, 60.4%, and 58.9% of participants were missing data on calcium, phosphate, 25-hydroxyvitamin D, and parathyroid hormone, respectively. These values were multiply imputed by the use of chained equations on the basis of observed baseline covariates. Multiple analyses over the imputations were combined by use of the Rubin rules to account for variability in the imputation procedure. 32 Missing covariate data accounted for <1% of variation in coefficient estimates. 
Results
Participant Characteristics
In MESA, the mean age was 62.0 years, 53.5% of participants were women, and 38.9% were white (Table 1) . Participants with higher serum FGF-23 concentrations were more likely to be female and white, to have diabetes mellitus, to use lipidlowering or antihypertensive medications, and to have a lower eGFR and a higher urine ACR. Participants with higher FGF-23 tended to have higher parathyroid hormone and 25-hydroxyvitamin D concentrations, but no significant differences in serum phosphate or calcium concentrations were observed. Higher FGF-23 concentration was directly correlated with LVED mass.
In CHS, the mean age was 77 years, 71.3% of participants were women, and 87.2% were white ( Table 2 ). In addition, compared with MESA, the mean eGFR was lower and geometric mean urine ACR was higher. Similar to MESA, participants with higher FGF-23 were more likely to use antihypertensive medications and tended to have a lower eGFR and a higher urine ACR. Higher FGF-23 was directly correlated with left atrial diameter but not LVED mass. In adjusted analyses, higher plasma FGF-23 concentration was associated with greater left atrial diameter after adjustment for demographic variables (Table IA in the online-only Data Supplement). This association was attenuated and no longer statistically significant with adjustment for potential confounders. Higher FGF-23 concentration was associated with LVED mass, and unlike left atrial diameter, this relationship remained strong and significant despite attenuation when fully adjusted (Table IB in 
FGF-23 and AF
In MESA, 291 incident AF events were observed, with an incidence rate of 6.2 per 1000 person-years. In CHS, 229 incident AF events were observed, with an incidence rate of 25.6 per 1000 person-years. In both MESA and CHS, higher FGF-23 concentrations were associated with higher unadjusted incidence rates of AF (Tables 3 and 4 and Figure 1, top) .
In adjusted analyses, the risk of incident AF increased monotonically with FGF-23 concentration in each cohort (Figure 1 In MESA, adjustment for left ventricular mass and volume, N-terminal pro-B-type natriuretic peptide, congestive heart failure events, or inflammatory markers did not attenuate the magnitude of association of FGF-23 with AF (Table V in the online-only Data Supplement). Similarly, in CHS, adjustment for left atrial diameter, congestive heart failure events, N-terminal pro-B-type natriuretic peptide, or C-reactive protein did not attenuate the magnitude of association of FGF-23 with AF (Table V in 
No significant heterogeneity in the association of FGF-23 concentration with AF was observed among subgroups defined by age, sex, or race/ethnicity (all P for interaction >0.1; Figure 2 ). The risk of AF associated with higher FGF-23 appeared to be somewhat greater in participants with low eGFR, elevated urine ACR, or CKD ( Figure 2 ). This heterogeneity was nominally significant only in evaluations of CKD and only in MESA (P for interaction=0.04).
Other Mineral Metabolism Markers
In analyses of MESA adjusted for demographics and potential confounding characteristics (as per model 2, Tables 3  and 4 ), each 0.5-mg/dL-higher serum phosphate concentration was associated with a 15% higher risk of incident AF (HR, 1.15; 95% CI, 1.02-1.31; P=0.023; 
Discussion
In 2 large community-based cohorts free of baseline cardiovascular disease, we demonstrated consistent associations of higher circulating FGF-23 concentration with increased risk of incident AF. These associations remained significant after accounting for other biomarkers of mineral metabolism, eGFR, urine ACR, and heart failure events. Adjusting for FGF-23 attenuated the association of low eGFR with incident AF in MESA, suggesting that FGF-23 may mediate, in part, the known association of CKD with AF. July 22, 2014 Seiler 11 Unlike our study, Seiler et al focused on participants in a specific clinical context with a high proportion of preexisting cardiovascular disease, raising the possibility of residual confounding. Moreover, they studied cross-sectional correlations with AF.
We were able to assess the development of new-onset AF over long-term follow-up in well-characterized, community-based populations without prevalent cardiovascular disease. This approach supports a temporal relationship between FGF-23 and AF while reducing the likelihood of confounding.
FGF-23 may be linked to AF through direct effects on the myocardium. 12 Higher circulating FGF-23 concentration has been associated with adverse cardiac remodeling, including greater left ventricular mass, an increased prevalence of left ventricular hypertrophy, and a lower ejection fraction. Similarly, among CHS participants in our study, higher concentrations of FGF-23 were strongly associated with greater left ventricular mass, as previously observed in a broader group of CHS participants that included those with baseline cardiovascular disease. 33 Interestingly, adjusting for left ventricular mass and size modestly attenuated the association between FGF-23 and AF in CHS but not MESA. These mediation analyses are limited by measurement of left ventricular dimensions at a single point in time, and as a result, the degree to which the association of FGF-23 with AF can be explained by left ventricular hypertrophy is not entirely clear.
12,13
Changes in left ventricular function may lead to increased left atrial size, a known risk factor for atrial dysrhythmias. In CHS, FGF-23 was correlated with left atrial size, but this association was attenuated and nonsignificant with adjustment for potential confounders. These results may reflect misclassification of left atrial size. 34 In the initial CHS echocardiographic reading, only left atrial anteroposterior diameter was measured. 35 Because the left atrium is an asymmetric, 3-dimensional structure that does not dilate uniformly, 1-dimensional left atrial measures ultimately fail to accurately capture the true extent of left atrial enlargement. 36 Because structural changes in the left ventricle and left atrium do not clearly explain the observed associations of FGF-23 with AF, other mechanisms should also be considered.
FGF-23 has been associated with endothelial dysfunction and vascular calcification, [37] [38] [39] [40] both of which could enhance automaticity and trigger episodes of AF. FGF-23 has also been associated with systemic inflammation. 41 AF is well known to be associated with an inflammatory milieu, 42, 43 and elevated C-reactive protein levels are a known risk factor for incident AF. 44 However, adjustment for single measures of C-reactive protein and interleukin-6 did not attenuate the association of FGF-23 with AF, making the role of these mechanisms unclear. Finally, the association of FGF-23 with AF could be mediated by inhibiting the production of 1,25(OH)2D, the active vitamin D hormone. The Paricalcitol Capsule Benefits in Renal Failure-Induced Cardiac Morbidity (PRIMO) trial examined the effects of a 1,25(OH)2D analog on cardiac structure over 48 weeks. 45 Although there were no differences between treatment and placebo groups with respect to the primary outcome of left ventricular mass index, there were significant differences in left atrial volume index, brain natriuretic peptide levels, and congestive heart failure hospitalizations between groups. 45, 46 In light of these findings, FGF-23 and 1,25(OH)2D may affect cardiac structure and function without an overt effect on the left ventricle.
Impaired GFR is a strong risk factor for AF, 19 and circulating FGF-23 concentrations rise markedly with progressive stages of CKD. [47] [48] [49] Therefore, kidney disease is an Results from Cox proportional hazards regression models for association of circulating fibroblast growth factor-23 (FGF-23) with incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis (MESA). Model 1 is adjusted for age, sex, race/ethnicity, study site, and attained education. Model 2 is additionally adjusted for low-density cholesterol, use of lipid-lowering medications, current smoking, diabetes mellitus, physical activity, height, height squared, weight, urine albumin-creatinine ratio, estimated glomerular filtration rate, systolic blood pressure, and use of hypertension medication. Model 3 is adjusted as per Model 2 with the addition of the serum concentrations of calcium, phosphate, 25-hydroxyvitamin D, and parathyroid hormone. Incidence rates are per 1000 person-years. P values are derived from the models assessing FGF-23 as a continuous variable. Results from Cox proportional hazards regression models for association of circulating fibroblast growth factor-23 (FGF-23) with incident atrial fibrillation in the Cardiovascular Health Study (CHS). Model 1 is adjusted for age, sex, race/ethnicity, study site, and attained education. Model 2 is additionally adjusted for low-density cholesterol, use of lipid-lowering medications, current smoking, diabetes mellitus, physical activity, height, height squared, weight, urine albumin-creatinine ratio, estimated glomerular filtration rate, systolic blood pressure, and use of hypertension medication. One potential explanation for this observation is that FGF-23 mediates, in part, the known association of eGFR with AF. Low eGFR was not associated with incident AF in CHS, with or without adjustment for FGF-23, perhaps because of the strong competing risk of death in this older population. 50 These observations implicate a renal-mineral metabolism axis that may play an important role in cardiovascular disease, including arrhythmogenesis. This relationship may be bidirectional. Recent studies suggest that successful arrhythmia suppression may depend on changes in renal function in patients with mild to moderate kidney disease and resistant hypertension. 51, 52 Alternatively, Bansal and colleagues 53 have shown that incident AF in a large population of patients with CKD was associated with a 67% increase in the rate of end-stage renal disease. FGF-23 may be an important catalyst in this bidirectional axis with both renal and cardiovascular implications.
Higher serum phosphate concentration was associated with increased risk of AF in MESA but not CHS. In the Atherosclerosis Risk in Communities Study (ARIC), another community-based cohort study, each 1-mg/dL-higher serum phosphate was associated with a 13% greater risk of incident AF. 9 In comparison, participants in MESA were free of cardiovascular disease at baseline, and the association of serum phosphate with incident AF was stronger. Reasons for heterogeneity across cohorts are not clear. Importantly, a single serum phosphate concentration may not be a robust marker of abnormal phosphate homeostasis. FGF-23 may be a more durable indicator of altered phosphate metabolism, potentially explaining the strong positive associations with AF observed in both MESA and CHS.
Our study has limitations. First, AF events were not adjudicated and were not classified by duration (paroxysmal versus persistent versus permanent). Second, FGF-23 did not improve AF risk prediction. However, we evaluated the contribution of FGF-23 to risk prediction in isolation, and a comprehensive evaluation of the renal-mineral metabolism axis may further improve risk prediction. It is important to note that a lack of clear difference in risk prediction does not eliminate an important role for FGF-23 in AF pathogenesis. Third, limited intermediate outcomes were available to evaluate potential mechanisms. Most important, the study is observational in nature, and observed associations may not be causal. In particular, there is a complex interplay between hormones regulating mineral metabolism, including 1,25(OH)2D, parathyroid hormone, and klotho, in addition to FGF-23, and this endocrine axis is strongly influenced by kidney disease. We adjusted for several markers of mineral metabolism, eGFR, and urine ACR, but residual confounding of the association of FGF-23 with AF may persist.
Strengths of our study include the community-based cohorts with broad ranges of age and racial/ethnic diversity, the longitudinal design, the ability to reduce potential confounding by the exclusion of participants with clinical cardiovascular disease and adjustment for well-ascertained potential confounding characteristics, the long duration of follow-up 
Conclusions
Higher circulating FGF-23 concentrations were associated with an increased risk of developing AF. Elevated FGF-23 may explain, in part, the excess risk of AF observed in CKD. 
